Abstract
A trypsin-resistant mutant of Sendai virus, TR-2, which could be activated by chymotrypsin but not by trypsin or the protease present in mouse lung, was inoculated intranasally into mice after being activated in vitro. TR-2 hardly brought about clinical illness or lung lesions in mice; the protease present in the lung could not activate the progeny virus, and the infection terminated after one-step replication. Nevertheless, the immunoglobulin A antibody against wild-type Sendai virus was produced in the respiratory tracts as well as the serum immunoglobulin G antibody, and the mice were protected from the challenge of the wild-type Sendai virus. On the basis of these results, TR-2 may provide a new model of live vaccine for paramyxoviruses; its availability as a live vaccine is also discussed.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference49 articles.
1. Pathogenesis of Sendai virus infection in mice;Appell L. H.;Am. J. Vet. Res.,1971
2. Activation of Sendai virus infectivity by an enzyme in chicken amniotic fluid;Appleyard G.;J. Gen. Virol.,1983
3. Studies of pulmonary and renal immunopathology after nonlethal primary Sendai virus infection in normal and cyclophosphamide-treated hamsters;Blandford G.;Am. Rev. Respir. Dis.,1977
4. Studies on the immune response and pathogenesis of Sendai virus infection of mice;Blandford G.;Immunology,1974
5. A comparison in germ-free mice of the pathogenesis of Sendai virus and mouse pneumonia virus infections;Carthew P.;J. Pathol.,1980
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献